var data={"title":"Mesalamine (mesalazine): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mesalamine (mesalazine): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6539?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mesalamine-mesalazine-drug-information\" class=\"drug drug_general\">see &quot;Mesalamine (mesalazine): Drug information&quot;</a> and <a href=\"topic.htm?path=mesalamine-mesalazine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mesalamine (mesalazine): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193412\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Apriso;</li>\n      <li>Asacol HD;</li>\n      <li>Canasa;</li>\n      <li>Delzicol;</li>\n      <li>Lialda;</li>\n      <li>Pentasa;</li>\n      <li>Rowasa;</li>\n      <li>SfRowasa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193413\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Asacol;</li>\n      <li>Asacol 800;</li>\n      <li>Mesasal;</li>\n      <li>Mezavant;</li>\n      <li>Pentasa;</li>\n      <li>Salofalk;</li>\n      <li>Teva-5 ASA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060194\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">5-Aminosalicylic Acid Derivative</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent, Rectal</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060188\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=mesalamine-mesalazine-drug-information\" class=\"drug drug_general\">see &quot;Mesalamine (mesalazine): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note</b>: Some oral products are not bioequivalent and should not be interchanged (ie, two Delzicol 400 mg capsules are not interchangeable or substitutable with one mesalamine 800 mg delayed release tablet).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Crohn disease; treatment (mild to moderate disease); maintenance of remission:</b> Limited data available: Children and Adolescents: Oral: 50 to 100 mg/kg/day divided every 6 to 12 hours (Fish 2004); maximum dose: 1,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ulcerative colitis; treatment (mild to moderate disease)</b>\n      <b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Delayed release capsule: Delzicol: Children &ge;5 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">17 to &lt;33 kg: Oral: 800 mg in the morning and 400 mg in the evening for 6 weeks; maximum daily dose: 1,200 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">33 to &lt;54 kg: Oral: 1,200 mg in the morning and 800 mg in the evening for 6 weeks; maximum daily dose: 2,000 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">54 to 90 kg: Oral: 1,200 mg in the morning and 1,200 mg in the evening for 6 weeks; maximum daily dose: 2,400 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing (including proctitis): Limited data available: Usual course of therapy is 3 to 8 weeks dependent on type of treatment: Children and Adolescents: Oral: 30 to 60 mg/kg/day divided every 6 to 12 hours; doses as high as 100 mg/kg/day have been used; maximum daily dose: 4,000 mg/day (Baldassano 1999; Fish 2004; Leichtner 1995; Tomomasa 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rectal: Limited data available: Older Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Enema: 4,000 mg once daily at bedtime (Baldassano 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Suppository: 500 mg once daily at bedtime; some have used twice daily (Baldassano 1999; Heyman 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Distal ulcerative colitis or proctosigmoiditis, active mild to moderate: Treatment:</b> Rectal: Retention enema: 4,000 mg at bedtime, retained overnight, approximately 8 hours. <b>Note: </b>Duration of rectal therapy is 3 to 6 weeks; some patients may require rectal and oral therapy concurrently.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ulcerative colitis</b>\n      <b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Oral: Usual course of therapy is 6 to 8 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Delzicol: 800 mg 3 times daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pentasa: 1,000 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Asacol HD: 1,600 mg 3 times daily for 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lialda: 2,400 to 4,800 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance of remissions: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Apriso: 1,500 mg once daily in the morning</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Delzicol: 1,600 mg/day in 2 to 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Pentasa: 1,000 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lialda: 2,400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ulcerative proctitis, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Retention enema: 4,000 mg at bedtime, retained overnight, approximately 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rectal suppository: 1,000 mg (1 suppository) rectally (retain for at least 1 to 3 hours) at bedtime for 3 to 6 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, dosage adjustments may be necessary since mesalamine is renally eliminated; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193391\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Delzicol: 400 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pentasa: 250 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pentasa: 500 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Apriso: 0.375 g [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Enema, Rectal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">SfRowasa: 4 g/60 mL (60 mL) [sulfite free; contains edetate disodium, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 g (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Rectal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rowasa: 4 g [contains edetate disodium, potassium metabisulfite, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 g</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suppository, Rectal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Canasa: 1000 mg (30 ea, 42 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Asacol HD: 800 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lialda: 1.2 g</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 800 mg, 1.2 g</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193376\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46780924\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asacol HD formulated <b>without</b> dibutyl phthalate (DBP) (NDC: 0023-5901-18) is available in the US as of May 2017.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asacol HD formulated <b>with</b> DBP (NDC: 00430-0783-27) may still be available in the marketplace and on pharmacy shelves.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060198\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule: Administer with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Apriso: Do not administer with antacids. The capsule should be swallowed whole per the manufacturer&rsquo;s labeling; however, opening the capsule and placing the contents (delayed release granules) on food with a pH &lt;6 is not expected to affect the release of mesalamine once ingested (data on file, Salix Pharmaceuticals Medical Information). There is no safety/efficacy information regarding this practice. The contents of the capsules should not be chewed or crushed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Delzicol: Swallow capsule whole with water; do not break, chew, crush, or cut. If a patient is unable to swallow the capsule, may open capsule and swallow capsule contents whole (do not cut, chew, break, or crush, or cut the contents). Ensure that all contents are swallowed and no contents are retained in the mouth.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pentasa: If a patient is unable to swallow the capsule, some clinicians support opening the capsules and placing the contents (controlled release beads) on yogurt or peanut butter (Crohn&rsquo;s &amp; Colitis Foundation of America). There are currently no published data evaluating the safety/efficacy of this practice. The contents of the capsules should not be chewed or crushed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Asacol HD: Take on an empty stomach, at least 1 hour before and 2 hours after a meal. Swallow tablets whole; do not break, chew, or crush; do not break outer coating.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lialda: Take with a meal. Swallow tablets whole; do not break outer coating.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Enema: Rowasa: Shake well before use. Instruct patient to lie on left side with left leg extended and right leg flexed forward for balance, or in &ldquo;knee-chest&rdquo; position. Insert lubricated applicator tip into the rectum and point slightly toward the navel. Grasp bottle firmly and tilt so nozzle is aimed toward the back; squeeze slowly to instill medication. After administration, withdraw and discard bottle. Retain enema for 8 hours or as long as practical</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suppository: Canasa: Remove foil wrapper; avoid excessive handling. Insert into rectum. Retain suppository for at least 1 to 3 hours for maximum benefit</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193408\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, tablet: Store between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F).  Protect capsules from moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Asacol HD, Delzicol: Store with desiccant pouch inside bottle with the capsules/tablets</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enema: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Use Rowasa promptly once foil wrap is removed; once the foil wrap is removed from a unit of seven sfRowasa bottles, discard any bottles remaining after 14 days. Contents may darken with time (do not use if dark brown).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suppository: Store below 25&deg;C (below 77&deg;F). May store under refrigeration. Protect from direct heat, light, and humidity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060197\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Treatment and/or maintenance of remission of ulcerative colitis (Delzicol: FDA approved in ages &ge;5 years and adults; Apriso, Asacol HD, Lialda, Pentasa: FDA approved in adults); has also been used for Crohn disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suspension enema: Treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis (Rowasa: FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suppository: Treatment of ulcerative proctitis (Canasa: FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193463\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Mesalamine may be confused with mecamylamine, megestrol, memantine, metaxalone, methenamine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Apriso may be confused with Apri</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Asacol may be confused with Ansaid, Os-Cal [DSC]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lialda may be confused with Aldara</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pentasa may be confused with Pancrease, Pangestyme</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193461\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects vary depending upon dosage form; frequency similar in adult and pediatric patients unless otherwise noted. Incidence usually on lower end with enema and suppository dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, fatigue, headache, nervousness, pain, paresthesia, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, alopecia, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased serum triglycerides, weight loss (children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, abdominal pain (children &amp; adolescents), anorectal pain (rectal; includes pain on insertion of enema tip), bloody diarrhea (children and adolescents), colitis, constipation, diarrhea, dyspepsia, eructation, exacerbation of ulcerative colitis, flatulence, gastroenteritis, gastrointestinal hemorrhage, hemorrhoids, lower abdominal pain, nausea, nausea and vomiting, pancreatitis (children and adolescents), rectal pain (rectal), sclerosing cholangitis (children and adolescents), tenesmus, upper abdominal pain, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria, urinary frequency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Decreased hematocrit, decreased hemoglobin, rectal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Cholestatic hepatitis, hepatic insufficiency, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection, influenza, viral infection (children and adolescents; adenovirus)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, arthropathy, back pain, leg pain (rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Decreased creatinine clearance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough (more common in children &amp; adolescents), dyspnea, nasopharyngitis (more common in children and adolescents), rhinitis, sinusitis (more common in children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, intolerance syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal cramps (rectal), abnormal stools, abnormal T waves on ECG, acute renal failure, agranulocytosis, albuminuria, amenorrhea, anaphylaxis, anemia, angioedema, anorectal pain (rectal; discomfort), anorexia, anxiety, aplastic anemia, arthritis, blurred vision, bronchitis, chest pain, chills, cholecystitis, cholestatic jaundice, chronic renal failure, confusion, conjunctivitis, decreased libido, depression, diaphoresis, DRESS syndrome, drowsiness, drug fever, duodenal ulcer, dysgeusia, dysmenorrhea, dysphagia, dysuria, ear disease, ecchymoses, eczema, edema, emotional lability, eosinophilia, eosinophilic pneumonitis, epididymitis, erythema, erythema nodosum, esophageal ulcer, Eustachian tube congestion, exacerbation of asthma, eye pain, facial edema, fecal discoloration (rectal), fecal incontinence, frequent bowel movements (rectal), gastritis, gout, granulocytopenia, Guillain-Barr&eacute; syndrome, hepatic cirrhosis, hepatic failure, hepatic injury, hepatic necrosis, hepatitis, hepatotoxicity, hyperesthesia, hypermenorrhea, hypersensitivity pneumonitis, hypersensitivity reaction, hypertonia, hypomenorrhea, hypotension, idiopathic nephrotic syndrome, increased amylase, increased appetite, increased blood urea nitrogen, increased gamma-glutamyl transferase, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin, increased serum creatinine, increased serum lipase, increased thirst, insomnia, interstitial nephritis, interstitial pneumonitis, interstitial pulmonary disease, intracranial hypertension, jaundice, Kawasaki-like syndrome, leg cramps, leukopenia, lichen planus, lupus-like syndrome, lymphadenopathy, malaise, male infertility (rectal), mastalgia, migraine, mucus stools (rectal), myalgia, myocarditis, nail disease, neck pain, nephrogenic diabetes insipidus, nephrotoxicity (rectal), neutropenia (rectal), oligospermia, oral candidiasis, oral mucosa ulcer, otalgia, painful defecation (rectal), palpitations, pancytopenia, perforated peptic ulcer, pericardial effusion, pericarditis, peripheral edema, peripheral neuropathy, pharyngitis, pharyngolaryngeal pain, pleurisy, pneumonitis, prurigo, pruritus, pruritus ani (rectal), psoriasis, pulmonary infiltrates, pulmonary fibrosis,pyoderma gangrenosum, rectal discharge (rectal), rectal polyp, renal disease (including minimal change nephropathy), renal insufficiency, renal failure, rheumatoid arthritis, skin photosensitivity, Stevens-Johnson syndrome, stomach discomfort (rectal), stomatitis, swelling of eye, systemic lupus erythematosus, tachycardia, thrombocythemia, thrombocytopenia, transverse myelitis, tremor, ulcerative colitis (rectal; pancolitis), urinary urgency, urticaria, uterine hemorrhage, vasodilatation, weakness, xeroderma, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193397\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to mesalamine, aminosalicylates, salicylates, or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe renal impairment (GFR &lt;30 mL/minute/1.73 m<sup>2</sup>); severe hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Additional contraindications per specific Canadian product labeling: Existing gastric or duodenal ulcer, urinary tract obstruction, use in children &lt;2 years of age (Asacol, Asacol 800, Mesasal, Pentasa, Salofalk); hemorrhagic diathesis (Mesasal); patients unable to swallow intact tablet (Asacol, Asacol 800); renal parenchymal disease (Pentasa)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193380\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac hypersensitivity effects: Pericarditis and myocarditis (mesalamine-induced cardiac hypersensitivity reactions) have been reported. Use with caution in patients predisposed to these conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Mesalamine-induced hypersensitivity reactions have been reported and may include internal organ involvement, such as hepatitis, hematologic abnormalities, and/or pneumonitis. Discontinue treatment for mesalamine-induced hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intolerance syndrome: May cause an acute intolerance syndrome (cramping, abdominal pain, bloody diarrhea; sometimes fever, headache, malaise, pruritus, rash, conjunctivitis); may be hard to discern from an exacerbation; discontinue immediately if syndrome occurs or is suspected. Symptoms usually abate if drug is discontinued. If rechallenge is performed to validate the hypersensitivity, use a reduced dose and only if clearly needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oligospermia: In males, oligospermia (rare, reversible) has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal effects: Renal impairment (including minimal change nephropathy, acute and chronic interstitial nephritis, nephrotic syndrome, and rarely renal failure) has been reported. A renal function evaluation is recommended prior to initiation of therapy and periodically during treatment. Mesalamine-induced nephrotoxicity should be suspected in patients developing renal impairment during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfasalazine hypersensitivity: Patients with hypersensitivity to sulfasalazine may react to mesalamine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use caution in patients with hepatic impairment; hepatic failure has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment, a history of renal disease, or those on nephrotoxic medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; uncontrolled studies and postmarketing reports suggest an increased incidence of blood dyscrasias (ie, agranulocytosis, neutropenia, pancytopenia) in patients &gt;65 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Apriso: Contains phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asacol HD (formulated without dibutyl phthalate [DBP]), Delzicol: Intact, partially intact, and/or tablet shells have been reported in the stool.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Canasa suppositories: Contain saturated vegetable fatty acid esters (contraindicated in patients with allergy to these components). May stain surfaces including clothing, other fabrics, flooring, painted surfaces, enamel, granite, marble and vinyl. Avoid contact with these surfaces.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rowasa enema: Contain metabisulfite salts that may cause severe hypersensitivity reactions (ie, anaphylaxis) in patients with sulfite allergies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rowasa, sfRowasa: May stain direct contact surfaces including clothing, other fabrics, flooring, painted surfaces, enamel, granite, marble and vinyl.  Choose a suitable location for product administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tablets: Patients with pyloric stenosis or other organic or functional upper gastrointestinal obstructive disorders may have prolonged gastric retention of tablets, delaying the release of mesalamine in the colon.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Asacol HD: Safety and effectiveness beyond 6 weeks have not been determined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bioequivalence: The Asacol HD 800 mg tablet has not been shown to be bioequivalent to two Delzicol 400 mg capsules. Two Delzicol 400 mg capsules have not been shown to be interchangeable or substitutable with one mesalamine 800 mg delayed-release tablet.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299675\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193385\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12584&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products. Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: 5-Aminosalicylic Acid Derivatives may decrease the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Heparin. Specifically, the risk for bleeding/bruising may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Heparins (Low Molecular Weight). Specifically, the risk for bleeding/bruising may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May diminish the therapeutic effect of Mesalamine. Histamine H2-Antagonist-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products. Management: Consider avoiding concurrent administration of high-dose histamine H2-receptor antagonists with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of 5-Aminosalicylic Acid Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products. Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiopurine Analogs: 5-Aminosalicylic Acid Derivatives may decrease the metabolism of Thiopurine Analogs. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varicella Virus-Containing Vaccines: 5-Aminosalicylic Acid Derivatives may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193387\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5304690\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Mesalamine is known to cross the placenta. An increased rate of congenital malformations has not been observed in human studies. Preterm birth, still birth and decreased birth weight have been observed; however, these events may also be due to maternal disease.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Dibutyl phthalate (DBP) may be an inactive ingredient in the enteric coating of some products (eg Asacol, Asacol HD); adverse effects in male rats were noted at doses greater than the recommended human dose. Refer to product labeling for current formulation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When treatment for inflammatory bowel disease is needed during pregnancy, mesalamine may be used, although products with DBP should be avoided (Habal 2012; Mottet 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49246102\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function (prior to and periodically during therapy); CBC; hepatic function; signs/symptoms of worsening acute intolerance syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193379\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">Mesalamine (5-aminosalicylic acid) is the active component of sulfasalazine; the specific mechanism of action is unknown; however, it is thought that mesalamine modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF); action appears topical rather than systemic</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193396\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rectal: Variable and dependent upon retention time, underlying GI disease, and colonic pH; Oral: Tablet: ~20% to 28%, Capsule: ~20% to 43%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Mesalamine (5-ASA): ~43%; N-acetyl-5-ASA: ~78%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic and via GI tract to N-acetyl-5-aminosalicylic acid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 5-ASA and N-acetyl-5-ASA: Variable; ~ 25 hours (range: 2 to 296 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule: Apriso: ~4 hours; Delzicol: ~10 hours; Pentasa: ~3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal: Pentasa, Salofalk [Canadian products]: 2 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: Asacol HD (formulated with dibutyl phthalate [DBP]): 10 to 16 hours; Asacol HD (formulated without DBP): ~24 hours (mean); Lialda: 9 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Canadian products: Asacol: 7 hours; Asacol 800: 10 hours; Mesasal: ~7 hours; Mezavant: 8 hours (range: 4 to 34 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral, suppository: Urine (primarily as N-acetyl-5-ASA, &le;12% as unchanged drug); feces (unabsorbed mesalamine)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Enema: Feces (primarily); urine (10% to 30%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193399\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Apriso Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.375 g (120): $577.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, controlled release</b> (Pentasa Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (240): $874.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (120): $874.43</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Delzicol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (180): $765.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Enema</b> (Mesalamine Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (60 mL): $24.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Enema</b> (SfRowasa Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g/60 mL (60 mL): $67.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Mesalamine-Cleanser Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (1): $171.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Rowasa Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 g (1): $476.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suppository</b> (Canasa Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg (30): $1,273.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Asacol HD Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (180): $1,854.79</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Lialda Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.2 g (120): $1,347.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Mesalamine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.2 g (120): $1,213.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">800 mg (180): $1,397.05</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F193402\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>5-ASA 400 (AR, PY);</li>\n      <li>Asacol (AE, BE, BH, CH, CY, DK, EG, ES, FI, GB, GR, HK, HR, IL, IT, JO, JP, KR, KW, LB, LU, LV, MT, MX, NL, NO, NZ, PK, PT, QA, SA, SE, SG, TW);</li>\n      <li>Asacolon (CO, IE);</li>\n      <li>Asakol (UA);</li>\n      <li>Asalit (BR);</li>\n      <li>Canasa (BD, CO);</li>\n      <li>Claversal (AT, BE, DE, ES, IT, LU, PT);</li>\n      <li>Colitofalk (BE, LU);</li>\n      <li>Coloncure (TW);</li>\n      <li>Huma-Col-Asa (HU);</li>\n      <li>Ibsol (LK);</li>\n      <li>Lialda (JP);</li>\n      <li>Lixacol (ES);</li>\n      <li>Mecolzine (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Mesacol (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Mesalin (KR);</li>\n      <li>Mesasal (AU, DK, NO, ZA);</li>\n      <li>Meslamin (BD);</li>\n      <li>Mezacol (AE, QA);</li>\n      <li>Mezavant (IE);</li>\n      <li>Mezavant XL (GB, HK, SG);</li>\n      <li>Octasa (GB);</li>\n      <li>Pentasa (AE, AU, BB, BE, BH, CH, CN, CY, DK, EG, ES, FR, GB, HK, HR, HU, IE, IQ, IR, IS, JO, JP, KW, LB, LU, LV, LY, MT, MY, NL, NO, OM, PH, QA, RO, RU, SA, SE, SG, SI, SK, SY, TH, TR, TW, VN, YE);</li>\n      <li>Pentasa Enema (NZ);</li>\n      <li>Pentasa SR (AE, BH, CY, EG, IL, IQ, IR, JO, KR, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Pentasa Tab (NZ);</li>\n      <li>Salofalk (AT, AU, BG, CH, CL, CN, CO, CZ, DE, EE, ES, GB, HK, HR, HU, ID, IE, KR, LK, LT, LV, MT, MY, NL, PE, PH, PL, RO, SG, SI, SK, TH, TR, UA, UY);</li>\n      <li>Salofalk Foam Enema (AU);</li>\n      <li>Suprimal (EC)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Apriso delayed release tablets (mesalamine) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Asacol HD delayed release tablets (mesalamine) [prescribing information]. Rockaway, NJ: Warner Chilcott; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Asacol HD delayed release tablets (mesalamine) [prescribing information]. Rockaway, NJ: Warner Chilcott; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baldassano RN and Piccoli DA, &quot;Inflammatory Bowel Disease in Pediatric and Adolescent Patients,&quot; <i>Gastroenterol Clin North Am</i>, 1999, 28(2):445-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesalamine-mesalazine-pediatric-drug-information/abstract-text/10372276/pubmed\" target=\"_blank\" id=\"10372276\">10372276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canasa rectal suppository (mesalamine) [prescribing information]. Bridgewater, NJ: Aptalis Pharma; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Delzicol (mesalamine) [prescribing information]. Rockaway, NJ: Warner Chilcott; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fish D and Kugathasan S, &quot;Inflammatory Bowel Disease,&quot; <i>Adolesc Med Clin</i>, 2004, 15(1):67-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesalamine-mesalazine-pediatric-drug-information/abstract-text/15272257/pubmed\" target=\"_blank\" id=\"15272257\">15272257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grand RJ, Ramakrishna J, and Calenda KA, &ldquo;Inflammatory Bowel Disease in the Pediatric Patient,&rdquo; <i>Gastroenterol Clin North Am</i>, 1995, 24(3):613-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesalamine-mesalazine-pediatric-drug-information/abstract-text/8809239/pubmed\" target=\"_blank\" id=\"8809239\">8809239</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habal FM and Huang VW, &quot;Review Article: A Decision-Making Algorithm for the Management of Pregnancy in the Inflammatory Bowel Disease Patient,&quot; <i>Aliment Pharmacol Ther</i>, 2012, 35(5):501-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesalamine-mesalazine-pediatric-drug-information/abstract-text/22221203/pubmed\" target=\"_blank\" id=\"22221203\">22221203</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heyman MB, Kierkus J, Sp&eacute;nard J, Shbaklo H, Giguere M. Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. <i>Inflamm Bowel Dis</i>. 2010;16(11):1931-1939.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesalamine-mesalazine-pediatric-drug-information/abstract-text/20848454 /pubmed\" target=\"_blank\" id=\"20848454 \">20848454 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leichtner AM, &quot;Aminosalicylates for the Treatment of Inflammatory Bowel Disease,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 1995, 21(3):245-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesalamine-mesalazine-pediatric-drug-information/abstract-text/8523207/pubmed\" target=\"_blank\" id=\"8523207\">8523207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lialda (mesalamine) [prescribing information]. Wayne, PA: Shire US Inc; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mottet C, Vader JP, Felley C, et al, &quot;Appropriate Management of Special Situations in Crohn's Disease (Upper Gastro-Intestinal; Extra-Intestinal Manifestations; Drug Safety During Pregnancy and Breastfeeding): Results of a Multidisciplinary International Expert Panel-EPACT II,&quot; <i>J Crohns Colitis</i>, 2009, 3(4):257-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesalamine-mesalazine-pediatric-drug-information/abstract-text/21172284/pubmed\" target=\"_blank\" id=\"21172284\">21172284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelis GF, &quot;Diarrhoea Due to 5-Aminosalicylic Acid in Breast Milk,&quot;<i> Lancet</i>, 1989, 1(8634):383.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesalamine-mesalazine-pediatric-drug-information/abstract-text/2563532/pubmed\" target=\"_blank\" id=\"2563532\">2563532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pentasa extended release capsules (mesalamine) [prescribing information]. Lexington, MA: Shire US Inc; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowasa suspension (mesalamine) [prescribing information]. Somerset, NJ: Meda Pharmaceuticals; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    sfRowasa rectal suspension (mesalamine) [prescribing information]. Somerset, NJ: Meda; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomomasa T, Kobayashi A, Ushijima K, et al, &quot;Guidelines for Treatment of Ulcerative Colitis in Children,&quot; <i>Pediatr Int</i>, 2004, 46(4):494-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mesalamine-mesalazine-pediatric-drug-information/abstract-text/15310325/pubmed\" target=\"_blank\" id=\"15310325\">15310325</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12584 Version 153.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F193412\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F193413\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060194\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060188\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F193391\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F193376\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F46780924\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060198\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F193408\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060197\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F193463\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F193461\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F193397\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F193380\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299675\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F193385\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F193387\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5304690\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F49246102\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F193379\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F193396\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F193399\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F193402\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12584|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mesalamine-mesalazine-drug-information\" class=\"drug drug_general\">Mesalamine (mesalazine): Drug information</a></li><li><a href=\"topic.htm?path=mesalamine-mesalazine-patient-drug-information\" class=\"drug drug_patient\">Mesalamine (mesalazine): Patient drug information</a></li></ul></div></div>","javascript":null}